crwefinancelogo2
signup3m
A5 Laboratories Inc. (OTC.BB:AFLB) has recently reported that the company has submitted a provisional patent application to protect its technology for its products. The patent application generally describes the company's new method for producing therapeutic proteins as well as providing details of the production of company's lead product VI-1718. A5 Lab's lead product VI-1718 has potential broad based applications for the treatment of certain types of cancer as well as multiple sclerosis and viral infections.
President and CEO of A5 Dr. Richard Azani stated The submission of this patent application is a very significant milestone in the development of our interferon-based products. I am very proud of our research team for their tireless work in completing the scientific and technological basis for this patent. We are now ready to advance the company's plans towards production and commercialization of these products.
AFLB is a contract research based organization servicing the pharmaceutical and biotechnology companies in North America. The company utilizes its research capabilities to license and acquire novel biotechnology products for development and commercialization.
XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, recently reported that the Committee for Orphan Medical Products of the European Medicines Agency (EMA) has adopted a positive opinion and recommends the granting of orphan medicinal product designation for XOMA 052, an antibody to interleukin-1 beta, for the treatment of Behcet's disease. Positive opinions are submitted to the European Commission for decision and are generally adopted within 30 days of receipt.
XOMA develops and manufactures novel antibody therapeutics for its own proprietary pipeline as well as through license and collaborative agreements with pharmaceutical and biotechnology companies, and under its contracts with the U.S. government.
http://crwefinance.com/img/crwefinance_new_buscard2.jpg
Signup for FREE Daily Stock Alerts From CRWEFinance.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more )Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under SEC Rule 17B. The fee may be in cash, in free trading stock, in restricted stock or in any combination thereof. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (CRWE.OB) has received eight thousand dollars in cash from a third party (Winning Media) for (one) day of advertising for A5 Laboratories Inc. (AFLB.OB)